These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Neuron-specific enolase as a serum marker for immature teratoma and dysgerminoma. Kawata M; Sekiya S; Hatakeyama R; Takamizawa H Gynecol Oncol; 1989 Feb; 32(2):191-7. PubMed ID: 2910781 [TBL] [Abstract][Full Text] [Related]
64. Establishment of radioimmunoassay for human macrophage colony-stimulating factor using recombinant human macrophage colony-stimulating factor as tracer and immunogen. Takahashi M; Ohmoto Y; Mizuno K; Yamanishi K; Hirai Y; Adachi M Biosci Biotechnol Biochem; 1993 Nov; 57(11):1838-43. PubMed ID: 7764334 [TBL] [Abstract][Full Text] [Related]
65. From the archives of the AFIP. Malignant germ cell tumors of the ovary: radiologic-pathologic correlation. Brammer HM; Buck JL; Hayes WS; Sheth S; Tavassoli FA Radiographics; 1990 Jul; 10(4):715-24. PubMed ID: 2165627 [TBL] [Abstract][Full Text] [Related]
66. [Plasma level of macrophage-colony stimulating factor (M-CSF) in the course of breast cancer treatment]. Lawicki S; Omyła J; Mroczko B; Szmitkowski M; Czygier M Pol Arch Med Wewn; 2004 Oct; 112(4):1181-7. PubMed ID: 15773430 [TBL] [Abstract][Full Text] [Related]
67. [Macrophage colony-stimulating factor (M-CSF) as a candidate for the tumor marker of breast cancer]. Ławicki S; Mroczko B; Omyła J; Czygier M; Szmitkowski M Pol Arch Med Wewn; 2003 Jun; 109(6):597-602. PubMed ID: 14582473 [TBL] [Abstract][Full Text] [Related]
69. Toward salivary-urinary chronosensitivity testing: chronomes of OVX1, M-CSF and CA130. Xu F; Yu Y; Bast RC; Cornélissen G; Fujii S; Takagi M; O'Brien T; Halberg F In Vivo; 1995; 9(4):407-12. PubMed ID: 8555442 [TBL] [Abstract][Full Text] [Related]
70. Quantitation of bovine macrophage colony-stimulating factor in bovine serum by ELISA. Yoshihara K; Oshima K; Muneta Y; Kikuma R; Yayota C; Hirai T; Satoh N; Matsuura S; Kikyo Y; Satoh M; Kubota C; Inumaru S; Yokomizo Y; Mori Y Vet Immunol Immunopathol; 2003 Oct; 95(3-4):103-11. PubMed ID: 12963271 [TBL] [Abstract][Full Text] [Related]
71. Circulating levels of CSF-1 (M-CSF) a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasms. Kacinski BM; Stanley ER; Carter D; Chambers JT; Chambers SK; Kohorn EI; Schwartz PE Int J Radiat Oncol Biol Phys; 1989 Jul; 17(1):159-64. PubMed ID: 2663797 [TBL] [Abstract][Full Text] [Related]
72. [Results of treatment of malignant ovarian tumors in children and adolescents]. Stasek V; Veselý K; Motlík K Cesk Gynekol; 1971 Oct; 36(8):466. PubMed ID: 5119859 [No Abstract] [Full Text] [Related]
77. [Advances in the therapy of malignant ovarian germ cell tumors]. Hong W Zhonghua Fu Chan Ke Za Zhi; 1996 Jul; 31(7):437-40. PubMed ID: 9275418 [No Abstract] [Full Text] [Related]
78. [Malignant germ cell neoplasms of the ovary. Experience with 40 cases]. Torres Lobatón A; Silva Pérez E; Mendoza Tenorio A; Romero Pinos M Ginecol Obstet Mex; 1983 Oct; 51(318):259-66. PubMed ID: 6681311 [No Abstract] [Full Text] [Related]
79. Serum levels of macrophage colony-stimulating factor in patients with ovarian cancer undergoing second-look laparotomy. Elg SA; Yu Y; Carson LF; Adcock LL; Twiggs LB; Prem KA; Ramakrishnan S Am J Obstet Gynecol; 1992 Jan; 166(1 Pt 1):134-7. PubMed ID: 1733183 [TBL] [Abstract][Full Text] [Related]